Data support potential of isaralgagene civaparvovec as a one-time, well tolerated and durable Fabry disease gene therapy to provide meaningful, multi-organ clinical benefits that could fundamentally ...
PolyPid Ltd. misses on earnings expectations. Reported EPS is $-0.41 EPS, expectations were $-0.34. Operator: Greetings and welcome to PolyPid’s Fourth Quarter and Full Year 2025 Conference Call.
ATLANTA - Artivion, Inc. (NYSE:AORT), a $1.93 billion market cap medical device company whose shares have surged 31.86% over the past six months, announced new clinical data from two trials evaluating ...
Request for FDA Rolling Review submitted to FDA on January 30, 2026 Non-Clinical and CMC BLA modules submitted to FDA At FDA's request, Type D Meeting expected in March 2026 to review Comparative ...
At FDA's request, Type D Meeting expected in March 2026 to review Comparative Oncology biomarker data from patients treated in OST-HER2 Phase 2b human clinical trial and OST-HER2 trial in spontaneous ...
ATLANTA, Feb. 2, 2026 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced the presentation of new clinical data from ...
New eTMF module integrates with Enlighten Clinical Solutions’ platform to support inspection-ready clinical trial documentation and execution. ATLANTA, GA, UNITED ...
GRAND BLANC, Mich., Dec. 10, 2025 /PRNewswire/ -- ModuleMD, ranked as one of America's fastest-growing companies on the Inc. 5000 and top-rated EHR vendor on G2, announces SkinSight™ AI, a solution ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results